Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Chemoradiotherapy vs Chemotherapy for Unresectable Locally Advanced Colon Cancer
NCT03970694Phase 3Terminated
- Sponsor
- Sun Yat-sen University
- Start
- May 2019
- Primary completion
- May 2022
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of oxaliplatin and capecitabine in colon cancer (2 arms), sponsored by Sun Yat-sen University. Primary endpoint: Overall Survival at 5 years. Started May 2019; status: terminated.
02
Drugs
oxaliplatincapecitabine
03
Conditions
colon cancer
Beyond the preview
Go deeper on NCT03970694.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03970694.